Rejection versus escape: the tumor MHC dilemma

Cancer Immunology, Immunotherapy

Volumn 66, Issue 2, 2017, Pages 259-271

  Garrido, Federico ^a,b,c   Ruiz Cabello, Francisco ^a,b,c   Aptsiauri, Natalia ^b,c  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^b IBS Instituto de Investigación Biosanitaria de Granada   (Spain)

^c UNIVERSITY OF GRANADA   (Spain)

Author keywords

Immune escape; MHC class I; PIVAC 15; Tumor rejection; Tumor tissue architecture; Tumor infiltrating lymphocytes

Indexed keywords

BETA 2 MICROGLOBULIN; HLA ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; HLA ANTIGEN CLASS 1;

ANTIGEN EXPRESSION; CANCER CELL; CANCER IMMUNOTHERAPY; CELL INFILTRATION; CHROMOSOME 15; CHROMOSOME 6; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; FIBROBLAST; GENE LOCUS; HUMAN; LEUKOCYTE; MACROPHAGE; MAJOR HISTOCOMPATIBILITY COMPLEX; METASTASIS; PHENOTYPE; PRIMARY TUMOR; PRIORITY JOURNAL; REVIEW; TISSUE STRUCTURE; TUMOR ESCAPE; TUMOR MICROENVIRONMENT; TUMOR REJECTION; ANIMAL; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASM;

ANIMALS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOTHERAPY; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR ESCAPE;

EID: 85007492393     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-016-1947-x     Document Type: Review

References (67)

1. Gorer PA (1937) The genetic and antigenic basis of tumor transplantation. J Pathol Bacteriol 44:691–697. doi:10.1002/path.1700440313
2. Foley EJ (1953) Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. Cancer Res 13:835–837
3. Baldwin RW (1955) Immunity to methylcholanthrene-induced tumors in inbred rats following atrophy and regression of implanted tumors. Br J Cancer 9:652–657
4. Prehn RT, Main JM (1957) Immunity to methylcholanthrene-induce sarcomas. J Natl Cancer Inst 18:769–778
5. Klein G, Sjogren HO, Klein E, Hellstrom KE (1960) Demonstration of resistance against methylcholanthreneinduced sarcomas in the primary autochthonous host. Cancer Res 20:1561–1572
6. Basombrio MA (1970) Search for common antigenicities among twenty-five sarcomas induced by methylcholanthrene. Cancer Res 30:2458–2462
7. Boon T, Coulie P, Van Den Eynde BJ, Van Der Bruggen P (2006) Human T cell responses against melanoma. Annu Rev Immunol 24:175–208
8. Townsend AR, Gotch FM, Davey J (1985) Cytotoxic T cells recognize fragments of the influenza nucleoprotein. Cell 42(2):457–467
9. Rosenberg SA, Lotze MT, Muul LM et al (1987) A progress report on the treatment of 157 patients with advance cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316(15):889–897
10. Tarhini AA, Gogas H, Kirkwood JM (2012) IFN-α in the treatment of melanoma. J Immunol 189(8):3789–3793
11. Morales A, Eidinger D, Bruce AW (1976) Intracavitary Bacillus Calmette Guerin in the treatment of superficial bladder tumors. J Urol 116(2):180–183
12. Andersen R, Donia M, Ellebaek E et al (2016) Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumour-infiltrating lymphocytes and an attenuated IL-2 regimen. Clin Cancer Res 22(15):3734–3745
13. Marchand M, Van Baren N, Weynan P et al (1999) Tumour regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 80:219–230
14. Spranger S, Koblish HK, Horton B, Scherle PA, Newton R, Gajewski TF (2014) Mechanism of tumor rejection with doublets of CTLA4, PD-1/PD-L1 or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment. J Immunother Cancer. doi:10.1186/2051-1426-2-3
15. Honeychurch J, Cheadle EJ, Dovedi SJ, Illidge TM (2015) Immunoregulatory antibodies for the treatment of cancer. Expert Opin Biol Ther 15:787–801
16. Ladanyi A, Somlai B, Gilde K, Fejös Z, Gaudi I, Tímár J (2004) T-cell activation marker expression on tumor-infiltrating lymphocytes as prognostic factor in cutaneous malignant melanoma. Clin Cancer Res 10(2):521–530
17. Schumacher K, Haensch W, Röefzaad C, Schlag PM (2001) Prognostic significance of activated CD8+ T cell infiltrations within esophageal carcinomas. Cancer Res 61:3932–3936
18. Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H et al (1998) CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 58:3491–3494
19. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C et al (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960–1964
20. Bodmer W, Browning MJ, Krausa P, Rowan A, Bicknell DC, Bodmer J (1993) Tumour escape from immune response by variation in HLA expression and other mechanism. Ann N Y Acad Sci 690:42–49
21. Garrido F, Cabrera T, Concha A, Glew S, Ruiz-Cabello F, Stern PL (1993) Natural history of HLA expression during tumour development. Immunol Today 14:491–499
22. Garrido F, Ruiz-Cabello F, Cabrera T, Perez-Villar JJ, Lopez-Botet M, Duggan-Keen M, Stern PL (1997) Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 18:89–95
23. Marincola FM, Jafee EM, Hicklin DJ, Ferrone S (2000) Escape of human solid tumors from T cell recognition: molecular mechanisms and functional significance. Adv Immunol 74:181–273
24. Garrido F, Algarra I (2001) MHC antigens and tumor escape from immune surveillance. Adv Cancer Res 83:117–158
25. Seliger B, Cabrera T, Garrido F, Ferrone S (2002) HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol 12:3–13
26. Koopman LA, Corver WE, Van Der Slik AR, Giphart MJ, Fleuren GJ (2000) Multiple genetic alterations at chromosome 6p cause frequent and heterogeneous HLA class I antigen loss in cervical cancer. J Exp Med 191:961–976
27. Ljunggren HG, Kärre K (1990) In search of the ‘missing self’: MHC molecules and NK cell recognition. Immunol Today 11(7):237–244
28. Stojanovic A, Correia MP, Cerwenka A (2013) Shaping of NK cell responses by the tumor microenvironment. Cancer Microenviron 6(2):135–146
29. Cabrera T, Lopez-Nevot MA, Gaforio JJ, Ruiz-Cabello F, Garrido F (2003) Analysis of HLA expression in human tumor tissues. Cancer Immunol Immunother 52:1–9
30. Garcia-Lora A, Algarra I, Gaforio JJ, Ruiz-Cabello F, Garrido F (2001) Immunoselection by T lymphocytes generates repeated MHC class I-deficient metastatic tumor variants. Int J Cancer 91:109–119
31. Garcia-Lora A, Martinez M, Algarra I, Gaforio JJ, Garrido F (2003) MHC class I-deficient metastatic tumor variants immunoselected by T lymphocytes originate from the coordinated downregulation of APM components. Int J Cancer 106:521–527
32. del Campo AB, Kyte JA, Carretero J, Zinchencko S, Méndez R, González-Aseguinolaza G, RuizCabello F, Aamdal S, Gaudernack G, Garrido F, Aptsiauri N (2014) Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma. Int J Cancer 134(1):102–113
33. Boon T, Coulie P, Van Den Eynde BJ, Van Der Bruggen P (2006) Human T cell responses against melanoma. Ann Rev Immunol 24:175–208
34. Romero P, Coulie P (2014) Adaptive T cell immunity and tumor antigen recognition. In: Rees R (ed) Tumor Immunology and Immunotherapy. Oxford University Press, Oxford, UK, pp 1–14
35. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Shadendorf D (1998) Vaccination of melanoma patients with peptide or tumor lysate-pulsed dendritic cells. Nat Med 4(3):328–332
36. Herbst RS, Baas P, Kim DW, Felip E et al (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387(10027):1540–1550. doi:10.1016/S0140-6736(15)01281-7
37. Carretero R, Romero JM, Ruiz-Cabello F, Maleno I, Rodriguez F, Camacho FM, Real LM, Garrido F, Cabrera T (2008) Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy. Immunogenetics 60:439–447
38. Carretero R, Wang E, Rodriguez AI, Reinboth J, Ascierto ML, Engle AM, Liu H, Camacho F, Marincola FM, Garrido F, Cabrera T (2012) Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes. Int J Cancer 131(2):387–395
39. Ryschich E, Notzel T, Hinz U, Autschbach F, Ferguson J, Simon I, Weitz J, Frohlich B, Klar E, Buchler M, Schmidt J (2005) Control of T cell mediated immune response by HLA class I in human pancreatic carcinoma. Clin Can Res 11:498–504
40. Kikuchi E, Yamazaki K, Torigoe T, Cho Y, Miyamoto M, Oizumi S, Hommura F, Dosaka-Akita H, Nishimura M (2007) HLA class I antigen expression is associated with a favorable prognosis in early stage non-small cell lung cancer. Cancer Sci 98:1424–1430
41. Garrido F, Cabrera T, Accola RS, Bensa JC, Bodmer W et al (1997) HLA and Cancer. In: Charron D (ed) HLA: genetic diversity of HLA. Functional and medical implications. EDK, Paris, pp 445–452
42. Mendez R, Ruiz-Cabello F, Rodriguez T, Del Campo A, Paschen A, Schadendorf D, Garrido F (2007) Identification of different tumor escape mechanisms in several metastases from a melanoma patient undergoing immunotherapy. Cancer Immunol Immunother 56(1):88–94
43. Tikidzhieva A, Benner A, Michel S, Formentini A, Link KH, Dippold W, von Knebel Doeberitz M, Kornmann M, Kloor M (2012) Microsatellite instability and Beta2-Microglobulin mutations as prognostic markers in colon cancer: results of the FOGT-4 trial. Br J Cancer 106(6):1239–1245
44. Garrido F, Romero I, Aptsiauri N, Garcia-Lora AM (2016) Generation of MHC class I diversity in primary tumors and selection of the malignant phenotype. Int J Cancer 138:271–280
45. Perea F, Bernal M, Sánchez-Palencia A, Carretero J, Torres C, Bayarri C, Gómez-Morales M, Garrido F, Ruiz-Cabello F (2017) The absence of HLA class I expression in non-small cell lung cancer correlates with the tumor tissue structure and the pattern of T cell infiltration. Int J Cancer 140(4):888–899
46. Mukhopadhyay S, Gal AA (2010) Granulomatous lung disease: an approach to the differential diagnosis. Arch Pathol Lab Med 134(5):667–690
47. Ramakrishnan L (2012) Revisiting the role of the granuloma in tuberculosis. Nat Rev Immunol 12:352–366
48. ThorStraten P, Garrido F (2016) Targetless T cells in cancer immunotherapy. J Immunother Cancer 4:23. doi:10.1186/s40425-016-0127-z
49. Bernal M, Ruiz-Cabello F, Concha A, Paschen A, Garrido F (2012) Implication of the β2 microglobulin gene in the generation of tumor escape phenotypes. Cancer Immunol Immunother 61(9):1359–1371
50. Garrido F, Cabrera T, Aptsiauri N (2010) “Hard” and “Soft” lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy. Int J Cancer 127(2):249–256
51. Maleno I, Cabrera CM, Cabrera T, Paco L, Lopez-Nevot MA, Collado A, Ferron A, Garrido F (2004) Distribution of HLA class I altered phenotypes in colorectal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Immunogenetics 56:244–253
52. Jimenez P, Canton J, Collado A, Cabrera T, Serrano A, Real LM, Garcia A, Ruiz-Cabello F, Garrido F (1999) Chromosome loss is the most frequent mechanism contributing to HLA haplotype loss in human tumors. Int J Cancer 83:91–97
53. Jimenez P, Cabrera T, Mendez R, Esparza C, Cozar JM, Tallada M, Lopez-Nevot MA, Ruiz-Cabello F, Garrido F (2001) A nucleotide insertion in exon 4 is responsible for the absence of expression of an HLA-A*0301 allele in a prostate carcinoma cell line. Immunogenetics 53:606–610
54. Serrano A, Brady CS, Jimenez P, Duggan-Keen MF, Mendez R, Stern P, Garrido F, Ruiz-Cabello F (2000) A mutation determining the loss of HLA-A2 antigen expression in a cervical carcinoma reveals novel splicing of human MHC class I classical transcripts in both tumoral and normal cells. Immunogenetics 51:1047–1052
55. Browning M, Petronzelli F, Bicknell D, Krausa P, Rowan A, Tonks S, Murray N, Bodmer J, Bodmer W (1996) Mechanisms of loss of HLA class I expression on colorectal tumour cells. Tissue Antigens 47(5):364–371
56. Seliger B, Ruiz-Cabello F, Garrido F (2008) IFN inducibility of major histocompatibility antigens in tumors. Adv Cancer Res 101:249–276
57. Garrido F, Aptsiauri N, Doordjuijn E, Garcia-Lora A, van Hall T (2016) The urgent need to recover MHC class I in cancers for effective immunotherapy. Curr Opin Immunol 39:44–51
58. Del Campo AB, Carretero J, Muñoz JA, Zinchenko S, Ruiz-Cabello F, González-Aseguinolaza G, Garrido F, Aptsiauri N (2014) Adenovirus expressing β2-microglobulin recovers HLA class I expression and antitumor immunity by increasing T-cell recognition. Cancer Gene Ther 21(8):317–332
59. Del Campo A, Aptsiauri N, Mendez R, Zinchenko S, Vales A, Paschen A, Ward S, Ruiz-Cabello F, González- Aseguinolaza G, Garrido F (2009) Efficient recovery of HLA class I expression in human tumor cells after beta2-microglobulin gene transfer using adenoviral vector: implications for cancer immunotherapy. Scand J Immunol 70:125–135
60. Carretero R, Cabrera T, Sáenz-López P, Maleno I, Aptsiauri N, Cózar JM, Garrido F (2011) Bacillus Calmette-Guerin immunotherapy of bladder cancer induces selection of human leukocyte antigen class I-deficient tumor cells. Int J Cancer 129(4):839–846
61. Corbiere V, Chapiro J, Stroobant V, Ma W, Lurquin C (2011) Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases. Cancer Res 71:1253–1262
62. Robert L, Tsoi J, Wang X, Emerson R, Homet B, Chodon T, Mok S, Huang RR, Cochran A, Comin-Anduix B, Koya R, Graeber T, Robins H, Ribas A (2014) CTLA4 blockade broadens the peripheral T cell receptor repertoire. Clin Cancer Res 20(9):2424–2432
63. Rodriguez T, Mendez R, Del Campo A, Jimenez P, Aptsiauri N, Garrido F, Ruiz-Cabello F (2007) Distinct mechanisms of loss of IFN-gamma mediated HLA class I inducibility in two melanoma cell lines. BMC Cancer 7:34
64. Kloor M, Becker C, Benner A, Woerner S, Gebert J, Ferrone S, Doeberitz MK (2005) Immunoselective pressure and human leukocyte antigen class I antigen machinery defects in microsatellite unstable colorectal cancers. Cancer Res 65:6418–6424
65. Angell TE, Lechner MG, Jang JK, LoPresti JS, Epstein AL (2014) MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro. Clin Cancer Res 20(23):6034–6044
66. Zaretsky JM, Angel Garcia-Diaz BS, Shin DS, Escuin-Ordinas H, Hugo W et al (2016) Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med 375(9):819–829
67. Aptsiauri N, Cabrera T, Mendez R, Garcia-Lora A, Ruiz-Cabello F, Garrido F (2007) Role of altered expression of HLA class I molecules in cancer progression. Adv Exp Med Biol 601:123–131